Article summary
Law360, London: Allergan plc remains on the hook for the bulk of a UK antitrust fine against the company and several other drugmakers for overcharging the National Health Service (NHS) hundreds of millions of pounds for hydrocortisone tablets, according to an appellate ruling on 18 September 2023.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial